BidaskClub upgraded shares of Concert Pharmaceuticals (NASDAQ:CNCE) from a hold rating to a buy rating in a research note issued to investors on Friday.

CNCE has been the subject of a number of other reports. Mizuho lowered Concert Pharmaceuticals from a buy rating to a neutral rating and set a $23.00 target price for the company. in a research note on Friday, January 12th. TheStreet upgraded Concert Pharmaceuticals from a c+ rating to a b- rating in a research report on Monday, January 8th. HC Wainwright reiterated a buy rating and issued a $21.00 price target on shares of Concert Pharmaceuticals in a research report on Friday, October 20th. UBS Group set a $34.00 price target on Concert Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, December 19th. Finally, ValuEngine cut Concert Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, January 16th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $24.33.

Shares of Concert Pharmaceuticals (NASDAQ CNCE) traded down $0.13 during midday trading on Friday, hitting $20.09. The company had a trading volume of 335,330 shares, compared to its average volume of 541,396. The firm has a market capitalization of $454.56, a price-to-earnings ratio of 5.36 and a beta of 1.23. Concert Pharmaceuticals has a twelve month low of $8.84 and a twelve month high of $30.71.

Concert Pharmaceuticals (NASDAQ:CNCE) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.16). Concert Pharmaceuticals had a net margin of 62.31% and a negative return on equity of 51.48%. sell-side analysts forecast that Concert Pharmaceuticals will post 4.1 EPS for the current fiscal year.

In other Concert Pharmaceuticals news, insider Value Fund L. P. Biotechnology sold 1,282,856 shares of the company’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $26.65, for a total value of $34,188,112.40. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Richard Aldrich sold 31,236 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $19.14, for a total value of $597,857.04. Following the completion of the sale, the director now owns 286,975 shares in the company, valued at $5,492,701.50. The disclosure for this sale can be found here. Insiders sold 1,433,248 shares of company stock worth $37,226,329 over the last quarter. Company insiders own 10.10% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its holdings in shares of Concert Pharmaceuticals by 57.2% during the fourth quarter. BlackRock Inc. now owns 1,786,223 shares of the biotechnology company’s stock worth $46,210,000 after purchasing an additional 649,808 shares during the last quarter. Ingalls & Snyder LLC grew its holdings in shares of Concert Pharmaceuticals by 8.7% during the fourth quarter. Ingalls & Snyder LLC now owns 1,314,562 shares of the biotechnology company’s stock worth $34,008,000 after purchasing an additional 105,500 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Concert Pharmaceuticals by 11.0% during the second quarter. Vanguard Group Inc. now owns 756,513 shares of the biotechnology company’s stock worth $10,553,000 after purchasing an additional 74,801 shares during the last quarter. Lyon Street Capital LLC grew its holdings in shares of Concert Pharmaceuticals by 6.5% during the third quarter. Lyon Street Capital LLC now owns 463,064 shares of the biotechnology company’s stock worth $6,830,000 after purchasing an additional 28,312 shares during the last quarter. Finally, Alyeska Investment Group L.P. grew its holdings in shares of Concert Pharmaceuticals by 1.8% during the third quarter. Alyeska Investment Group L.P. now owns 368,243 shares of the biotechnology company’s stock worth $5,432,000 after purchasing an additional 6,576 shares during the last quarter. Institutional investors own 67.20% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Concert Pharmaceuticals (CNCE) Raised to Buy at BidaskClub” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/02/10/concert-pharmaceuticals-cnce-raised-to-buy-at-bidaskclub.html.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.